United Therapeutics (UTHR) Tops Q3 EPS by 120c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
- Qualcomm shares fall on Intel warning and legal concerns
- Marvell Technology shares drop on Lumentum deal concerns
- Oracle shares drop on AI spending concerns and Microsoft criticism
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- SpaceX stock drops on launch setback and sector selloff
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Cowen Remains Bullish on United Therapeutics (UTHR) as Orenitram Continues to Grow
October 27, 2015 4:01 PM EDTCowen reiterated an Outperform rating and $185.00 price target on United Therapeutics Corp. (NASDAQ: UTHR) following the company's 3Q15 earnings results. All pulmonary hypertension products beat expectations, driving revenue and EPS above consensus.
Analyst Phil Nadeau commented, "UTHR reported strong Q3 results this morning. All pulmonary... More
Leerink Partners Reiterates Market Perform Following United Therapeutics (UTHR) 3Q beat
October 27, 2015 1:44 PM EDTLeerink Partners reiterated a Market Perform rating and $166.00 price target on United Therapeutics Corp. (NASDAQ: UTHR) following the company's 3Q15 earnings report. UTHR reported 3Q revenues and non-GAAP EPS of $386M and $3.55 that beat Street estimates of $362M and $3.22. Management reported that sales... More



